Adalimumab | ECCO E-Guide
European Crohn´s and Colitis Organisation - ECCO - OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease - Clinical Gastroenterology and Hepatology
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial - The Lancet Gastroenterology & Hepatology
IJMS | Free Full-Text | A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
PDF) Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial
ECCO-EFCCA Patient Guidelines on Crohn's Disease (CD)
JCM | Free Full-Text | The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator | Scientific Reports
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
PDF) Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies
IJMS | Free Full-Text | The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding
Adalimumab | ECCO E-Guide
Biomedicines | Free Full-Text | The New Proactive Approach and Precision Medicine in Crohn's Disease
Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay | Science Translational Medicine
Frontiers | Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
European Crohn´s and Colitis Organisation - ECCO - Volume 14, Issue 2
Cureus | Use of Azathioprine in Ulcerative Colitis: A Comprehensive Review | Article
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease - Gastroenterology
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease | NEJM
![PDF] Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/434bc5078bbc62a1a4782f27592fcf28f239679e/8-Table2-1.png "PDF] Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. | Semantic Scholar")
PDF] Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. | Semantic Scholar
Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis | European Journal of Medical Research | Full Text
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? | Nature Reviews Gastroenterology & Hepatology
Full article: Management of Crohn's disease in poor responders to adalimumab
